查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2068738

數位糖尿病管理市場預測至2034年－按產品、設備連接方式、糖尿病類型、通路、部署模式、最終用戶和地區分類的全球分析

Digital Diabetes Management Market Forecasts to 2034 - Global Analysis By Product (Devices, Software & Platforms, and Services), Device Connectivity, Diabetes Type, Distribution Channel, Deployment Mode, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球數位糖尿病管理市場預計將在 2026 年達到 82 億美元，到 2034 年達到 246 億美元，在預測期內以 14.7% 的複合年成長率成長。

數位化糖尿病管理是指由互聯設備、軟體平台和遠端服務組成的整合生態系統，旨在幫助患者和醫療專業人員監測、管理和最佳化糖尿病治療。這些解決方案包括持續血糖監測儀、智慧胰島素筆、行動應用程式和人工智慧驅動的決策支援工具，它們結合使用，能夠實現即時血糖值追蹤，並為每位患者提供個人化的治療方案調整。透過將患者產生的數據與臨床工作流程結合，這些技術可以減少糖尿病相關併發症，降低住院率，並賦能個人積極參與自身長期代謝健康的管理。

全球糖尿病盛行率不斷上升，慢性病負擔日益加重

全球第2型糖尿病負擔的迅速加重，迫切需要醫療保健系統採用擴充性的、技術驅動的管理解決方案。在患者數量不斷成長而臨床資源仍然有限的情況下，數位化平台提供了一種切實可行的持續護理途徑，且不會成比例地增加人事費用。即時傳輸血糖值的連網設備能夠實現及時的臨床干預，從而預防急性惡化。保險公司日益認知到主動式數位化監測和住院預防所帶來的後續成本節約，這推動了報銷支持，並加速了這些平台在各種醫療保健機構中的廣泛應用。

資料隱私問題和監管合規挑戰

由於數位化糖尿病管理工具處理高度敏感的健康數據，因此它們面臨 HIPAA 和 GDPR 等法規的嚴格合規義務。供應商必須在網路安全基礎設施、資料加密和稽核機制方面投入巨資，以滿足監管要求。一些具有特定人口統計特徵的患者不願與第三方平台共用其持續的生物辨識數據，這阻礙了此類工具的普及。此外，全球監管環境的碎片化意味著，在某一司法管轄區獲得批准的設備可能需要在其他地區獲得漫長的額外核准，這顯著增加了旨在拓展國際市場的創新者的上市時間和研發成本。

擴大遠端患者監護的報銷範圍

北美和歐洲的政府及私人保險公司正逐步改善慢性病管理中遠端患者監護的報銷機制。這項政策轉變顯著降低了醫療服務提供者實施數位化糖尿病解決方案以及患者使用這些解決方案的經濟門檻。報銷機制的確定性將鼓勵對下一代動態血糖監測系統和閉合迴路胰島素輸注平台的投資。新興市場，特別是東南亞地區，也正在推動遠距遠端醫療相關的政策改革，催生新的目標市場。隨著支付方框架的日趨成熟，那些已建立起強力的基於結果的計費模式臨床證據的供應商有望獲得可觀的合約金額。

醫療設備與電子健康記錄之間互通性的差距。

數位糖尿病設備與醫院電子健康記錄系統之間缺乏無縫資料交換，導致臨床工作流程受阻，並降低了互聯解決方案的價值。當臨床醫生必須手動將患者報告的數據與診所的測量數據進行核對時，節省時間的優勢便蕩然無存，人們對數位工具的信任度也隨之下降。主要醫療設備製造商採用的專有數據標準進一步阻礙了與第三方系統的整合。由於缺乏通用的互通性協議，醫療機構不願在無法與其現有基礎設施原生通訊的平台上投入大量預算。

新型冠狀病毒（COVID-19）的影響：

新冠疫情初期，由於限制了面對面就診，糖尿病診療服務面臨挑戰，但也凸顯了遠距監測的效用。醫院迅速擴展了遠端醫療能力，並建立了慢性病管理的線上諮詢服務。醫療設備製造商加快了雲端連接技術的研發，監管機構也發布了數位健康工具的緊急使用授權。疫情後，人們對慢性病脆弱性的認知不斷提高，推動了對預防性數位醫療的持續投資。儘管初期供應鏈受到干擾，但市場正朝著長期持續成長的方向發展。

在預測期內，醫療設備領域預計將佔據最大的市場佔有率。

在預測期內，受持續血糖監測（CGM）系統和智慧胰島素筆強勁且持續的需求驅動，設備細分市場預計將佔據最大的市場佔有率。硬體是數位化糖尿病生態系統中至關重要的實體接點，CGM感測器價格高昂，並能帶來耗材的重複銷售。目標患者群體正在穩步擴大，同時越來越多的臨床指南建議所有類型的糖尿病患者使用CGM，而感測器成本也在不斷下降。成熟的設備製造商和新興的新創公司都在投資研發更小巧、更耐用的感測器，以保持其在該領域的市場主導地位。

預計在預測期內，基於人工智慧的決策支援工具細分市場將呈現最高的複合年成長率。

在預測期內，xx細分市場預計將呈現最高的成長率。基於大規模縱向資料集訓練的機器學習演算法現在可以提前數小時預測高血糖和低血糖的發生，從而實現真正的預防性干預。與閉合迴路胰島素輸注系統的整合進一步提升了其臨床價值。製藥公司和數位健康公司正在聯合投資於演算法的檢驗研究，以加速法規核准。人工智慧決策支援技術已成為更廣泛的數位糖尿病領域中成長最快的創新技術之一。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這主要得益於已開發國家中最高的糖尿病人均盛行率以及完善的持續血糖監測（CGM）設備保險報銷系統。美國在CGM設備的普及應用方面處於領先地位，這得益於其獲得FDA已通過核准的在研設備、成熟的私人保險體係以及美國糖尿病協會（ADA）推薦持續監測的臨床指南。數位醫療領域活躍的創業投資活動，以及醫院系統致力於強制推行慢性病遠距監測項目，為該地區持續集中收入創造了有利環境。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於中國、印度和東南亞糖尿病病例的快速成長。都市區收入的提高和中產階級健康意識的增強，推動了對便利、互聯的自我管理解決方案的需求。該地區各國政府正大力投資數位醫療基礎設施，當地製造商也正在開發符合當地經濟狀況、具成本競爭力的動態血糖監測（CGM）設備。疾病盛行率的上升、網路連線的改善以及各國保險報銷政策的不斷完善，共同推動了亞太地區在全球數位糖尿病管理領域最具活力的成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球數位糖尿病管理市場：依產品分類

  • 裝置
    • 連續血糖監測（CGM）系統
    • 智慧型血糖儀
    • 胰島素幫浦
    • 智慧胰島素筆
    • 穿戴式糖尿病管理設備
  • 軟體平台
    • 行動應用
    • 基於雲端的資料管理平台
    • 糖尿病分析軟體
    • 人工智慧驅動的決策支援工具
  • 服務
    • 遠端監控服務
    • 數位輔導服務
    • 遠端醫療服務
    • 訂閱式糖尿病管理計劃

第6章：全球數位糖尿病管理市場：設備連結性

  • 支援藍牙的設備
  • 支援NFC功能的設備
  • 支援 Wi-Fi 的設備
  • 智慧型手機相容設備
  • 雲端連線系統

第7章 全球數位化糖尿病管理市場：依糖尿病類型分類

  • 1型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病
  • 糖尿病前期

第8章：全球數位糖尿病管理市場：按分銷管道分類

  • 線上平台
  • 零售藥房
  • 醫院藥房
  • 直接面對消費者的銷售管道

第9章：全球數位糖尿病管理市場：依部署模式分類

  • 基於雲端的解決方案
  • 本地部署解決方案
  • 混合解決方案

第10章 全球數位糖尿病管理市場：以最終用戶分類

  • 醫院和診所
  • 居家照護環境
  • 診斷中心
  • 學術研究機構
  • 患者/個人用戶
  • 付款人和保險公司

第11章 全球數位糖尿病管理市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Abbott Laboratories
  • DexCom, Inc.
  • Medtronic plc
  • Insulet Corporation
  • F. Hoffmann-La Roche Ltd.
  • Ascensia Diabetes Care Holdings AG
  • LifeScan, Inc.
  • Tandem Diabetes Care, Inc.
  • B. Braun Melsungen AG
  • Sanofi SA
  • Glooko, Inc.
  • Senseonics Holdings, Inc.
  • DarioHealth Corp.
  • Ypsomed Holding AG
  • ARKRAY, Inc.
Product Code: SMRC37046

According to Stratistics MRC, the Global Digital Diabetes Management Market is accounted for $8.2 billion in 2026 and is expected to reach $24.6 billion by 2034, growing at a CAGR of 14.7% during the forecast period. Digital Diabetes Management refers to an integrated ecosystem of connected devices, software platforms, and remote services that assist patients and clinicians in monitoring, managing, and optimizing diabetes care. These solutions encompass continuous glucose monitors, smart insulin pens, mobile applications, and AI-driven decision support tools that collectively enable real-time tracking of glucose levels and personalized treatment adjustments. By bridging patient-generated data with clinical workflows, these technologies reduce diabetes-related complications, lower hospitalizations, and empower individuals to take an active role in their own long-term metabolic health management.

Market Dynamics:

Driver:

Rising global prevalence of diabetes and chronic disease burden

The accelerating global burden of Type 2 diabetes is compelling healthcare systems to adopt scalable, technology-driven management solutions. As patient populations expand and clinical resources remain constrained, digital platforms offer a viable path to continuous care without proportionally increasing workforce costs. Connected devices transmit glucose readings in real time, enabling timely clinical interventions that prevent acute episodes. Payers are increasingly recognizing the downstream cost savings of preventing hospitalizations through proactive digital monitoring, fueling reimbursement support and accelerating widespread institutional adoption of these platforms across diverse healthcare settings.

Restraint:

Data privacy concerns and regulatory compliance challenges

Digital diabetes tools handle sensitive health data, creating significant compliance obligations under regulations such as HIPAA and GDPR. Vendors must invest heavily in cybersecurity infrastructure, data encryption, and audit mechanisms to satisfy regulatory requirements. Patients in certain demographics express hesitancy about sharing continuous biometric data with third-party platforms, limiting adoption. Additionally, the fragmented global regulatory landscape means that devices cleared in one jurisdiction may require lengthy additional approvals elsewhere, substantially increasing time-to-market and development costs for innovators seeking international scale.

Opportunity:

Expansion of remote patient monitoring reimbursement frameworks

Governments and commercial insurers across North America and Europe are progressively formalizing reimbursement pathways for remote patient monitoring in chronic disease management. This policy shift significantly lowers the financial barrier for both providers deploying and patients accessing digital diabetes solutions. Reimbursement certainty incentivizes investment in next-generation CGM systems and closed-loop insulin delivery platforms. Emerging markets, particularly across Southeast Asia, are also witnessing telehealth policy reforms, creating new addressable markets. Vendors that build strong clinical evidence for outcomes-based billing models stand to capture substantial contract value as payer frameworks mature.

Threat:

Interoperability gaps between devices and electronic health records

The persistent lack of seamless data exchange between digital diabetes devices and hospital electronic health record systems creates friction in clinical workflows, reducing the perceived value of connected solutions. When clinicians must manually reconcile patient-reported data with in-clinic measurements, time savings evaporate and trust in digital tools erodes. Proprietary data standards used by major device manufacturers further hinder third-party integration. Without universal interoperability protocols, healthcare institutions are reluctant to commit significant budget to platforms that cannot natively communicate with their existing infrastructure.

Covid-19 Impact:

The COVID-19 pandemic initially strained diabetes care delivery by limiting in-person clinic visits, but simultaneously validated the utility of remote monitoring. Hospitals rapidly expanded telehealth capabilities, normalizing virtual consultations for chronic disease management. Device manufacturers accelerated cloud connectivity features, while regulators issued emergency use authorizations for digital health tools. Post-pandemic, heightened awareness of chronic disease vulnerability has driven sustained investment in preventive digital care, positioning the market for durable long-term expansion despite early supply chain disruptions.

The Devices segment is expected to be the largest during the forecast period

The Devices segment is expected to account for the largest market share during the forecast period, driven by strong and ongoing demand for continuous glucose monitoring (CGM) systems and smart insulin pens. Hardware represents the essential physical touchpoint of the digital diabetes ecosystem, with CGM sensors commanding premium pricing and repeat consumable sales. Growing clinical guidelines endorsing CGM use across all diabetes types, combined with falling sensor costs, are steadily broadening the addressable patient base. Established device makers and emerging start-ups alike are investing in miniaturized, longer-wear sensors to sustain this segment's market leadership.

The AI-Based Decision Support Tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the xx segment is predicted to witness the highest growth rate. Machine learning algorithms trained on large longitudinal datasets are now capable of anticipating hyperglycemic and hypoglycemic events hours in advance, enabling truly preventive interventions. Integration with closed-loop insulin delivery systems further amplifies clinical value. Pharmaceutical companies and digital health firms are co-investing in algorithm validation studies to accelerate regulatory clearance, positioning AI decision support as the fastest-growing innovation frontier within the broader digital diabetes landscape.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the highest per-capita diabetes prevalence among developed economies and well-established reimbursement pathways for CGM devices. The United States leads adoption, supported by FDA-cleared device pipelines, a mature private insurance ecosystem, and clinical guidelines from the American Diabetes Association endorsing continuous monitoring. Strong venture capital activity in digital health, combined with hospital system mandates for chronic disease remote monitoring programs, provides a favorable environment for sustained revenue concentration in this region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, propelled by a rapidly expanding diabetic population across China, India, and Southeast Asia. Rising urban incomes and expanding middle-class health consciousness are driving demand for convenient, connected self-management solutions. Governments in the region are investing heavily in digital health infrastructure, and local manufacturers are developing cost-competitive CGM devices tailored to regional affordability. The convergence of growing disease prevalence, improving internet connectivity, and evolving national reimbursement policies makes Asia Pacific the most dynamic growth frontier in global digital diabetes management.

Key players in the market

Some of the key players in Digital Diabetes Management Market include Abbott Laboratories, DexCom, Inc., Medtronic plc, Insulet Corporation, F. Hoffmann-La Roche Ltd., Ascensia Diabetes Care Holdings AG, LifeScan, Inc., Tandem Diabetes Care, Inc., B. Braun Melsungen AG, Sanofi S.A., Glooko, Inc., Senseonics Holdings, Inc., DarioHealth Corp., Ypsomed Holding AG, ARKRAY, Inc.

Key Developments:

In March 2026, Abbott Laboratories Abbott Laboratories announced the commercial launch of its next-generation FreeStyle Libre 4 continuous glucose monitoring sensor in key European markets, featuring an extended 15-day wear period and enhanced Bluetooth connectivity for seamless integration with third-party insulin delivery devices.

In January 2026, DexCom, Inc. DexCom entered into a strategic collaboration agreement with a leading pharmacy benefit manager to integrate its G7 CGM system into employer-sponsored diabetes prevention programs, aiming to expand access to real-time glucose monitoring for high-risk individuals across the United States.

Products Covered:

  • Devices
  • Software & Platforms
  • Services

Device Connectivities Covered:

  • Bluetooth Enabled
  • NFC Enabled
  • Wi-Fi Enabled
  • Smartphone Integrated
  • Cloud Connected

Diabetes Types Covered:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Prediabetes

Distribution Channels Covered:

  • Online Platforms
  • Retail Pharmacies
  • Hospital Pharmacies
  • Direct-to-Consumer Channels

Deployment Modes Covered:

  • Cloud-Based Solutions
  • On-Premise Solutions
  • Hybrid Solutions

End Users Covered:

  • Hospitals & Clinics
  • Homecare Settings
  • Diagnostic Centers
  • Academic & Research Institutes
  • Patients/Individual Users
  • Payers & Insurance Providers

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Diabetes Management Market, By Product

  • 5.1 Devices
    • 5.1.1 Continuous Glucose Monitoring (CGM) Systems
    • 5.1.2 Smart Glucose Meters
    • 5.1.3 Insulin Pumps
    • 5.1.4 Smart Insulin Pens
    • 5.1.5 Wearable Diabetes Devices
  • 5.2 Software & Platforms
    • 5.2.1 Mobile Applications
    • 5.2.2 Cloud-Based Data Management Platforms
    • 5.2.3 Diabetes Analytics Software
    • 5.2.4 AI-Based Decision Support Tools
  • 5.3 Services
    • 5.3.1 Remote Monitoring Services
    • 5.3.2 Digital Coaching Services
    • 5.3.3 Telemedicine Services
    • 5.3.4 Subscription-Based Diabetes Management Programs

6 Global Digital Diabetes Management Market, By Device Connectivity

  • 6.1 Bluetooth Enabled Devices
  • 6.2 NFC Enabled Devices
  • 6.3 Wi-Fi Enabled Devices
  • 6.4 Smartphone Integrated Devices
  • 6.5 Cloud Connected Systems

7 Global Digital Diabetes Management Market, By Diabetes Type

  • 7.1 Type 1 Diabetes
  • 7.2 Type 2 Diabetes
  • 7.3 Gestational Diabetes
  • 7.4 Prediabetes

8 Global Digital Diabetes Management Market, By Distribution Channel

  • 8.1 Online Platforms
  • 8.2 Retail Pharmacies
  • 8.3 Hospital Pharmacies
  • 8.4 Direct-to-Consumer Channels

9 Global Digital Diabetes Management Market, By Deployment Mode

  • 9.1 Cloud-Based Solutions
  • 9.2 On-Premise Solutions
  • 9.3 Hybrid Solutions

10 Global Digital Diabetes Management Market, By End User

  • 10.1 Hospitals & Clinics
  • 10.2 Homecare Settings
  • 10.3 Diagnostic Centers
  • 10.4 Academic & Research Institutes
  • 10.5 Patients/Individual Users
  • 10.6 Payers & Insurance Providers

11 Global Digital Diabetes Management Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Abbott Laboratories
  • 14.2 DexCom, Inc.
  • 14.3 Medtronic plc
  • 14.4 Insulet Corporation
  • 14.5 F. Hoffmann-La Roche Ltd.
  • 14.6 Ascensia Diabetes Care Holdings AG
  • 14.7 LifeScan, Inc.
  • 14.8 Tandem Diabetes Care, Inc.
  • 14.9 B. Braun Melsungen AG
  • 14.10 Sanofi S.A.
  • 14.11 Glooko, Inc.
  • 14.12 Senseonics Holdings, Inc.
  • 14.13 DarioHealth Corp.
  • 14.14 Ypsomed Holding AG
  • 14.15 ARKRAY, Inc.

List of Tables

  • Table 1 Global Digital Diabetes Management Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Digital Diabetes Management Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Digital Diabetes Management Market Outlook, By Devices (2023-2034) ($MN)
  • Table 4 Global Digital Diabetes Management Market Outlook, By Continuous Glucose Monitoring (CGM) Systems (2023-2034) ($MN)
  • Table 5 Global Digital Diabetes Management Market Outlook, By Smart Glucose Meters (2023-2034) ($MN)
  • Table 6 Global Digital Diabetes Management Market Outlook, By Insulin Pumps (2023-2034) ($MN)
  • Table 7 Global Digital Diabetes Management Market Outlook, By Smart Insulin Pens (2023-2034) ($MN)
  • Table 8 Global Digital Diabetes Management Market Outlook, By Wearable Diabetes Devices (2023-2034) ($MN)
  • Table 9 Global Digital Diabetes Management Market Outlook, By Software & Platforms (2023-2034) ($MN)
  • Table 10 Global Digital Diabetes Management Market Outlook, By Mobile Applications (2023-2034) ($MN)
  • Table 11 Global Digital Diabetes Management Market Outlook, By Cloud-Based Data Management Platforms (2023-2034) ($MN)
  • Table 12 Global Digital Diabetes Management Market Outlook, By Diabetes Analytics Software (2023-2034) ($MN)
  • Table 13 Global Digital Diabetes Management Market Outlook, By AI-Based Decision Support Tools (2023-2034) ($MN)
  • Table 14 Global Digital Diabetes Management Market Outlook, By Services (2023-2034) ($MN)
  • Table 15 Global Digital Diabetes Management Market Outlook, By Remote Monitoring Services (2023-2034) ($MN)
  • Table 16 Global Digital Diabetes Management Market Outlook, By Digital Coaching Services (2023-2034) ($MN)
  • Table 17 Global Digital Diabetes Management Market Outlook, By Telemedicine Services (2023-2034) ($MN)
  • Table 18 Global Digital Diabetes Management Market Outlook, By Subscription-Based Diabetes Management Programs (2023-2034) ($MN)
  • Table 19 Global Digital Diabetes Management Market Outlook, By Device Connectivity (2023-2034) ($MN)
  • Table 20 Global Digital Diabetes Management Market Outlook, By Bluetooth Enabled Devices (2023-2034) ($MN)
  • Table 21 Global Digital Diabetes Management Market Outlook, By NFC Enabled Devices (2023-2034) ($MN)
  • Table 22 Global Digital Diabetes Management Market Outlook, By Wi-Fi Enabled Devices (2023-2034) ($MN)
  • Table 23 Global Digital Diabetes Management Market Outlook, By Smartphone Integrated Devices (2023-2034) ($MN)
  • Table 24 Global Digital Diabetes Management Market Outlook, By Cloud Connected Systems (2023-2034) ($MN)
  • Table 25 Global Digital Diabetes Management Market Outlook, By Diabetes Type (2023-2034) ($MN)
  • Table 26 Global Digital Diabetes Management Market Outlook, By Type 1 Diabetes (2023-2034) ($MN)
  • Table 27 Global Digital Diabetes Management Market Outlook, By Type 2 Diabetes (2023-2034) ($MN)
  • Table 28 Global Digital Diabetes Management Market Outlook, By Gestational Diabetes (2023-2034) ($MN)
  • Table 29 Global Digital Diabetes Management Market Outlook, By Prediabetes (2023-2034) ($MN)
  • Table 30 Global Digital Diabetes Management Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 31 Global Digital Diabetes Management Market Outlook, By Online Platforms (2023-2034) ($MN)
  • Table 32 Global Digital Diabetes Management Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 33 Global Digital Diabetes Management Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 34 Global Digital Diabetes Management Market Outlook, By Direct-to-Consumer Channels (2023-2034) ($MN)
  • Table 35 Global Digital Diabetes Management Market Outlook, By Deployment Mode (2023-2034) ($MN)
  • Table 36 Global Digital Diabetes Management Market Outlook, By Cloud-Based Solutions (2023-2034) ($MN)
  • Table 37 Global Digital Diabetes Management Market Outlook, By On-Premise Solutions (2023-2034) ($MN)
  • Table 38 Global Digital Diabetes Management Market Outlook, By Hybrid Solutions (2023-2034) ($MN)
  • Table 39 Global Digital Diabetes Management Market Outlook, By End User (2023-2034) ($MN)
  • Table 40 Global Digital Diabetes Management Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 41 Global Digital Diabetes Management Market Outlook, By Homecare Settings (2023-2034) ($MN)
  • Table 42 Global Digital Diabetes Management Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 43 Global Digital Diabetes Management Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 44 Global Digital Diabetes Management Market Outlook, By Patients/Individual Users (2023-2034) ($MN)
  • Table 45 Global Digital Diabetes Management Market Outlook, By Payers & Insurance Providers (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.